Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bioregenx (BRGX) Shares Outstanding (Weighted Average) (2021 - 2025)

Bioregenx's Shares Outstanding (Weighted Average) history spans 5 years, with the latest figure at $959.7 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $959.7 million for Q4 2025, up 5.19% from a year ago — trailing twelve months through Dec 2025 was $959.7 million (up 5.19% YoY), and the annual figure for FY2025 was $959.7 million, up 5.19%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $959.7 million at Bioregenx, roughly flat from $960.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $960.9 million in Q3 2025 to a low of $269.7 million in Q4 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $764.3 million (2023), against an average of $670.3 million.
  • The sharpest move saw Shares Outstanding (Weighted Average) changed 0.0% in 2022, then soared 183.34% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $269.7 million in 2021, then changed by 0.0% to $269.7 million in 2022, then skyrocketed by 137.18% to $639.8 million in 2023, then surged by 42.61% to $912.4 million in 2024, then rose by 5.19% to $959.7 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $959.7 million, $960.9 million, and $959.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.